At Hyperspace Ventures, we’re always on the lookout for bold ideas and brilliant teams that are reshaping the future. That’s why we’re thrilled to announce our latest investment in PinPrint, an exciting startup co-founded by renowned health tech innovator Renee Ryan and Joseph DeSimone, a pioneering scientist and co-founder of Carbon.

PinPrint is on a mission to reinvent how patients experience vaccines and drug therapies, leveraging the powerful potential of software-powered 3D printing. They aim to make medical treatments more personalized, precise, and accessible, marking a transformative step forward in the intersection of healthcare and technology. Their lead innovation is a next-generation microneedle patch designed to deliver vaccines and active agents intradermally, replacing the need for traditional injections. "By integrating high-resolution 3D printing with advanced drug delivery, we're redefining the patient experience across therapeutic and cosmetic categories, offering a new standard for precision, personalization, and comfort," said Dr. DeSimone.

This investment places Hyperspace Ventures alongside a formidable group of backers, including Continuity Biosciences, LLC, Fox Ventures, and the Carolina Angel Network. PinPrint is powered by a seed note, exclusive strategic licenses, and an impressive portfolio of strategic patents.

We’re proud to welcome PinPrint as the fourth company to receive funding from our SPV (Special Purpose Vehicle) investment program, which supports visionary startups with capital, community, and strategic insight. They now stand alongside other companies we've back, Learn to Win, Bezel, and Pickleball Inc. Each are leaders in their respective industries.

To receive access for this and future exclusive investment opportunities, fill out this form.

Learn more about PinPrint here.